Suppr超能文献

环丙沙星,一种对需氧菌和厌氧菌均有活性的喹诺酮羧酸化合物。

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

作者信息

Chin N X, Neu H C

出版信息

Antimicrob Agents Chemother. 1984 Mar;25(3):319-26. doi: 10.1128/AAC.25.3.319.

Abstract

The in vitro activity of ciprofloxacin, a quinolone-carboxylic acid derivative, was compared with those of norfloxacin, cefotaxime, cephalexin, ceftazidime, moxalactam, amoxicillin, and methicillin and other agents, as appropriate. The MICs of ciprofloxacin for 90% of members of the family Enterobacteriaceae and for Pseudomonas aeruginosa, Neisseria spp., and Bacteroides fragilis were between 0.005 and 0.8 micrograms/ml, whereas streptococci and staphylococci were all inhibited by less than or equal to 6.3 micrograms/ml. Ciprofloxacin was 4- to 32-fold more active than norfloxacin and inhibited gentamicin-, ameikacin-, cefotaxime-, and moxalactam-resistant members of the family Enterobacteriaceae and P. aeruginosa and methicillin-resistant Staphylococcus aureus. The activity of ciprofloxacin was not affected by serum but decreased in the presence of acid urine. The frequency of resistance to ciprofloxacin was between 10(-7) and 10(-9).

摘要

将喹诺酮羧酸衍生物环丙沙星的体外活性与诺氟沙星、头孢噻肟、头孢氨苄、头孢他啶、拉氧头孢、阿莫西林、甲氧西林及其他相关药物的活性进行了比较。环丙沙星对90%的肠杆菌科菌属以及铜绿假单胞菌、奈瑟菌属和脆弱拟杆菌的最低抑菌浓度(MIC)在0.005至0.8微克/毫升之间,而链球菌和葡萄球菌均被小于或等于6.3微克/毫升的浓度所抑制。环丙沙星的活性比诺氟沙星高4至32倍,并且能抑制对庆大霉素、阿米卡星、头孢噻肟和拉氧头孢耐药的肠杆菌科菌属及铜绿假单胞菌,以及耐甲氧西林金黄色葡萄球菌。环丙沙星的活性不受血清影响,但在酸性尿液中活性会降低。对环丙沙星的耐药频率在10^(-7)至10^(-9)之间。

相似文献

1
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Mar;25(3):319-26. doi: 10.1128/AAC.25.3.319.
2
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
3
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
4
The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
J Antimicrob Chemother. 1984 Apr;13(4):325-31. doi: 10.1093/jac/13.4.325.
5
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
J Antimicrob Chemother. 1984 Apr;13(4):333-46. doi: 10.1093/jac/13.4.333.
6
In vitro activity of ciprofloxacin (Bay o 9867).
Antimicrob Agents Chemother. 1983 Oct;24(4):568-74. doi: 10.1128/AAC.24.4.568.
7
In-vitro activity of newer quinolones against aerobic bacteria.
J Antimicrob Chemother. 1986 Apr;17 Suppl B:29-39. doi: 10.1093/jac/17.suppl_b.29.
8
The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
J Antimicrob Chemother. 1986 Aug;18(2):163-9. doi: 10.1093/jac/18.2.163.
10
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
Antimicrob Agents Chemother. 1984 May;25(5):633-7. doi: 10.1128/AAC.25.5.633.

引用本文的文献

2
Ciprofloxacin-Loaded Spray-Dried Lactose Particles: Formulation Optimization and Antibacterial Efficacy.
Pharmaceutics. 2025 Mar 20;17(3):392. doi: 10.3390/pharmaceutics17030392.
3
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.
Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022.
4
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.
Molecules. 2021 Nov 25;26(23):7153. doi: 10.3390/molecules26237153.
7
Engineering Fluorine into Verticillins (Epipolythiodioxopiperazine Alkaloids) via Precursor-Directed Biosynthesis.
J Nat Prod. 2019 Nov 22;82(11):3104-3110. doi: 10.1021/acs.jnatprod.9b00711. Epub 2019 Oct 21.
8
Antibacterial Efficacy of Sutures Coated With and Ciprofloxacin: A Comparative Evaluation.
J Pharm Bioallied Sci. 2019 May;11(Suppl 2):S164-S168. doi: 10.4103/JPBS.JPBS_284_18.
9
Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance.
Drug Dev Res. 2019 Feb;80(1):33-47. doi: 10.1002/ddr.21468. Epub 2018 Oct 10.
10
Application of a Physiologically Based Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With Ciprofloxacin and Caffeine.
CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):74-81. doi: 10.1002/psp4.12061. Epub 2016 Feb 16.

本文引用的文献

1
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
Antimicrob Agents Chemother. 1980 Feb;17(2):103-8. doi: 10.1128/AAC.17.2.103.
2
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
Eur J Clin Microbiol. 1983 Apr;2(2):111-5. doi: 10.1007/BF02001575.
3
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
4
Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.
Antimicrob Agents Chemother. 1983 Jan;23(1):188-9. doi: 10.1128/AAC.23.1.188.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验